Apogee Therapeutics (APGE) Total Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Total Liabilities data on file, last reported at $37.9 million in Q1 2026.

• Quarterly Total Liabilities fell 7.2% year-over-year to $37.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.9 million (down 7.2% YoY) and the FY2025 annual result came in at $33.3 million, down 10.51% from the prior year.
• Total Liabilities advanced to $37.9 million in Q1 2026 per APGE's latest filing, from $33.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $46.6 million in Q1 2023 and bottomed at $4.4 million in Q2 2022.
• The 5-year median for Total Liabilities is $30.1 million (2024), against an average of $28.7 million.
• The widest annual swing landed in 2023, when Total Liabilities surged 297.36%; it then tumbled 52.45% in 2024.
• Tracing APGE's Total Liabilities over 5 years: stood at $10.0 million in 2022, then jumped by 115.34% to $21.5 million in 2023, then jumped by 72.9% to $37.2 million in 2024, then retreated by 10.51% to $33.3 million in 2025, then rose by 13.86% to $37.9 million in 2026.
• Per Business Quant, the three latest APGE Total Liabilities figures stand at $37.9 million (Q1 2026), $33.3 million (Q4 2025), and $39.8 million (Q3 2025).

Peer Comparison